PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
|Videos|March 28, 2022
Robotic Aseptic Fill-Finish: A Game-Changing Flexible Solution
Author(s)Pii
Advertisement
Pii’s Robotic Aseptic Fill-Finish
Pii’s Robotic Aseptic Fill-Finish line provides reliable and flexible processing, minimizes manual interventions, and reduces product losses, common at the beginning and end of batch manufacturing. The Robotic Aseptic Fill-Finish line compliments Pii’s larger volume production lines by offering clinical fill-finish manufacturing of cartridges, vials and syringes. With Batch Sizes from 1L – 1000L, Pii is your preferred Aseptic Fill-Finish CDMO.
Pii’s Large Scale Aseptic Fill-Finish
Pii’s Bosch Aseptic Fill-Finish line is perfect for handling large commercialization batches, filling up to 150-200 vials per minute. The Bosch accommodates both Ready to Use (RTU) and Ready to Sterilize (RTS) vials 2mL – 100mL.Pii is your preferred Aseptic Fill-Finish CDMO.
Pii's Aseptic Vial Fill-Finish
Pii’s M and O Perry Aseptic Fill-Finish line offers clinical and commercial fill-finish manufacturing of vials filling up to 40 vials per minute. This line supports batch sizes from (1L – 500L) and the ability to fill a vial size range from 3mL – 100mL. Pii is your preferred Aseptic Fill-Finish CDMO.
Pii’s Aseptic Pre-Filled Syringe Fill-Finish
Pii’s Groninger Syringe Fill-Finish line supports a range of injectables from clinical to commercial batch sizes up to 50,000 syringes per day with pre-filled syringe sizes ranging from 1mL – 10mL. Pii is your preferred Aseptic Fill-Finish CDMO.
Advertisement
Related to this article
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
3
FDA's IND Pilot Puts CMC Review First
4
Successful Internal Audit Planning and Execution
5